Bisphosphonate binding affinity affects drug distribution in both intracortical and trabecular bone of rabbits

Calcified Tissue International

Volumn 90, Issue 3, 2012, Pages 202-210

  Turek, John ^a,b   Ebetino, F Hal ^c   Lundy, Mark W ^b   Sun, Shuting ^d   Kashemirov, Boris A ^d   McKenna, Charles E ^d   Gallant, Maxime A ^b   Plotkin, Lilian I ^b   Bellido, Teresita ^b   Duan, Xuchen ^e   Triffitt, James T ^e   Russell, R Graham G ^e   Burr, David B ^b   Allen, Matthew R ^b  

^a PURDUE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c Dundalk   (Ireland)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Anti remodeling; Drug accumulation; Fluorescent bisphosphonate; Skeletal distribution

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BONE TURNOVER; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CORTICAL BONE; EXPERIMENTAL RABBIT; FEMALE; LUMBAR VERTEBRA; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; RIB; TIBIA; TISSUE DISTRIBUTION; TRABECULAR BONE; VERTEBRA; ANIMAL; BINDING COMPETITION; BINDING SITE; BONE; BONE REMODELING; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECT; HAVERSIAN CANAL; METABOLISM; OSTEOCYTE; OSTEOPOROSIS; PHYSIOLOGY; RABBIT;

ANIMALS; BINDING SITES; BINDING, COMPETITIVE; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DIPHOSPHONATES; FEMALE; HAVERSIAN SYSTEM; OSTEOCYTES; OSTEOPOROSIS; RABBITS; TISSUE DISTRIBUTION;

EID: 84868330857     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-012-9570-0     Document Type: Article

References (31)

1. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W., Mangood A, Russell RG, Ebetino F.H. (2006) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38: 617-627
2. Ebetino FH, Hogan A-ML, Sun S, Tsoumpra M.K., Duan X., Triffitt JT, Kwaasi AA, Dunford JE, Barnett B.L., Oppermann U., Lundy MW, Boyde A, Kashemirov BA, McKenna C.E., Russell RGG (2011) The relationship between the chemistry and biological activity of the bisphosphonates. Bone 49: 20-33
3. Russell RG, Watts NB, Ebetino FH, Rogers M.J. (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19: 733-759
4. Sato M, Grasser W, Endo N, Akins R, Simmons H., Thompson DD, Golub E, Rodan G.A. (1991) Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88: 2095-2105
5. Roelofs AJ, Coxon FP, Ebetino FH, Lundy MW, Henneman Z.J., Nancollas GH, Sun S, Blazewska KM, Lynn FBJ, Kashemirov BA, Khalid A.B., McKenna CE, Rogers M.J. (2009) Fluorescent risedronate analogs reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res 25: 606-616
6. Kozloff KM, Volakis LI, Marini JC, Caird M.S. (2010) Near-infrared fluorescent probe traces bisphosphonate delivery and retention in vivo. J Bone Miner Res 25: 1748-1758
7. Roelofs AJ, Boyde A, Lundy MW, McKenna CE, Blazewska K, Sun S.T., Kashemirov BA, Russell RGG, Ebetino FH, Rogers M.J., Coxon F.P. (2009) Bone mineral affinity influences the distribution of a bisphosphonate and a lower affinity analogue in vivo. Bone 44: S430-S431
8. Boyde A, Lundy MW, Coxon FP, McKenna CE, Roelofs A, Bala J., Rogers MJ, Blazewska K, Russell RGG, Ebetino F.H. (2009) The differential distribution in vivo of fluorescently-labeled bis-phosphonate analogues with different mineral affinity to bone surfaces. Bone 44: S57
9. Roelofs A, Stewart CA, Sun S, Blazewska K, Kashemirov BA, McKenna C.E., Russell RGG, Rogers MJ, Lundy M.W., Ebetino FH, Coxon F.P. (2011) Influence of bone affinity on the skeletal distribution of fluorescently-labeled bisphosphonates in vivo. J Bone Miner Res (in press)
10. Kashemirov BA, Bala JLF, Chen X, Ebetino F., Xia Z, Russell RGG, Coxon FP, Roelofs A.J., Rogers MJ, McKenna CE (2008) Fluorescently labeled risedronate and related analogues: magic linker synthesis. Bioconjug Chem 19: 2308-2310
11. Liu H, Ren G, Miao Z, Zhang X, Tang X., Han P, Gambhir SS, Cheng Z, Boswell A. (2010) Molecular optical imaging with radioactive probes. PLoS One 5: e9470
12. Plotkin LI, Aguirre JI, Kousteni S, Manolagas SC, Bellido T. (2005) Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem 280: 7317-7325
13. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas S.C., Bellido T. (1999) Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104: 1363-1374
14. Sun S, Blazewska KM, Kashemirov BA, Roelofs AJ, Coxon F.P., Rogers MJ, Ebetino FH, McKenna MJ, McKenna C.E. (2011) Synthesis and characterization of novel fluorescent nitrogen-containing bisphosphonate imaging probes for bone active drugs. Phosphorus Sulfur Silicon Relat Elem 186: 970-971
15. Wu D, Boyd R, Fix T, Burr D.B. (1990) Regional patterns of bone loss and altered bone remodeling in response to calcium deprivation in laboratory rabbits. Calcif Tissue Int 47: 18-23
16. Mashiba T, Burr DB, Turner CH, Sato M, Cain RL, Hock J.M. (2001) Effects of human parathyroid hormone (1-34), LY333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbits. Bone 28: 538-547
17. Allen MR, Iwata K, Phipps R, Burr D.B. (2006) Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 39: 872-879
18. Abramoff MD, Magalhaes P, Ram S. (2004) Image processing with ImageJ. Biophoton Int 11: 36-43
19. Allen MR, Kubek DJ, Burr D.B. (2010) Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs. J Bone Miner Res 25: 98-105
20. Fleisch H, Russell RGG, Francis M.D. (1969) Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165: 1262
21. Borah B, Dufresne T, Nurre J, Phipps R, Chmielewski P., Wagner L, Lundy M, Bouxsein M., Zebaze R, Seeman E. (2010) Risedronate reduces intracortical porosity in women with osteoporosis. J Bone Miner Res 25: 41-47
22. Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzl P, Klaushofer K. (2001) Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29: 185-191
23. Allen MR, Reinwald S, Burr D.B. (2008) Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment. Calcif Tissue Int 82: 354-360
24. Smith SY, Recker RR, Hannan M, Muller R, Bauss F. (2003) Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 32: 45-55
25. Bellido T, Plotkin L.I. (2011) Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone 49: 50-55
26. Silverman SL, Watts NB, Delmas PD, Lange JL, Lindsay R. (2007) Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendr-onate (REAL) cohort study. Osteoporos Int 18: 25-34
27. Khosla S, Riggs BL, Atkinson EJ, Oberg AL, McDaniel L.J., Holets M., Peterson JM, Melton LJ III (2006) Effects of sex and age on bone microstructure at the ultradistal radius: a population based noninvasive in vivo assessment. J Bone Miner Res 21: 124-131
28. Recker RR, Kimmel DB, Parfitt MA, Davies MK, Keshawarz N, Hinders S. (1988) Static and tetracycline based bone histomor-phometric data from 34 normal postmenopausal females. J Bone Miner Res 3: 133-144
29. Sim FH, Kelly P. (1970) Relationship of bone remodeling, oxygen consumption, and blood flow in bone. J Bone Joint Surg 52: 1377
30. Morris MA, Kelly P.J. (1980) Use of tracer microspheres to measure bone blood flow in conscious dogs. Calcif Tissue Int 32: 69-76
31. Whiteside LA, Simmons DJ, Lesker P.A. (1977) Comparison of regional bone blood flow in areas with differing osteoblastic activity in the rabbit tibia. Clin Orthop Relat Res 124: 267